Hangzhou Tigermed Consulting Full Year 2024 Earnings: Misses Expectations

Hangzhou Tigermed Consulting (SZSE:300347) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥6.60b (down 11% from FY 2023).
• Net income: CN¥405.1m (down 80% from FY 2023).
• Profit margin: 6.1% (down from 27% in FY 2023).
• EPS: CN¥0.47 (down from CN¥2.34 in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hangzhou Tigermed Consulting Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) also missed analyst estimates by 64%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Life Sciences industry in China.

Performance of the Chinese Life Sciences industry.

The company's shares are down 5.8% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 2 warning signs for Hangzhou Tigermed Consulting that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.